Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X

• Published in: European journal of clinical investigation 2000-10, Vol.30 (10), p.871-878
• Main Authors: Idzior-Walus, B., Sieradzki, J., Rostworowski, W., Zdzienicka, A., Kawalec, E., Wójcik, J., Żarnecki, A., Blane, G.
• Format: Article
• Language: English
• Subjects: Adult; Alanine Transaminase - blood; Alkaline Phosphatase - blood; Aspartate Aminotransferases - blood; Biological and medical sciences; Blood Glucose; Blood Pressure - drug effects; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Creatine Kinase - blood; Dyslipoproteinemia; Fasting; fenofibrate; Fenofibrate - administration & dosage; gamma-Glutamyltransferase - blood; General and cellular metabolism. Vitamins; Glucose Tolerance Test; Hemostasis - drug effects; hemostatic factors; Humans; hypertension; Hypertension - blood; Hypertension - drug therapy; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; hyperuricemia; Hypolipidemic Agents - administration & dosage; Insulin - blood; Insulin Resistance - physiology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; syndrome X; Uric Acid - blood
• ISSN: 0014-2972; 1365-2362
• DOI: 10.1046/j.1365-2362.2000.00734.x

Background This study investigated the effects of comicronised fenofibrate in patients with dyslipidemia and polymetabolic syndrome X. Design After a 6‐week dietary run‐in phase, 37 male patients eligible on lipid criteria entered a 12‐week treatment phase consisting of diet plus one capsule daily containing 200 mg of comicronised fenofibrate (Lipanthyl®). Results A significant reduction in plasma concentrations of total cholesterol, LDL cholesterol and triglyceride was observed after 4, 8 and 12 weeks of treatment with fenofibrate. The improvement in the atherogenic index LDL/HDL cholesterol from a pretreatment 3.8 to 3.0 after treatment was highly statistically significant and may be judged as satisfactory. Significant changes were also observed in haemostatic factors (fibrinogen reduced by 19%, factor VII activity reduced by 18%). Fasting serum insulin levels and insulin response (area under the curve) after oral glucose load were significantly reduced by 26.8% and 18.7%, respectively, indicating an improvement of insulin sensitivity. Systolic and diastolic blood pressure were significantly reduced. Uric acid was significantly reduced by 21.6%. Conclusion These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X.